IL1B and colitis: Interestingly, our study demonstrated that blocking the MyD88-mediated immunological pathway alone could not ameliorate DSS-induced colitis severity in terms of body weight loss, DAI, histological change, and several proinflammatory cytokine levels including TNF-α, IFN-γ, and IL-1β, although the activation of NF-κB was significantly inhibited.